Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II investigator-initiated trial of DSP-7888 in acute myeloid leukemia
jRCT2051200023Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2020
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adegramotide + nelatimotide in acute myeloid leukemia (AML), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Relapse-free survival. Started Jun 2020; status: active, not recruiting.
02
Drugs
adegramotide + nelatimotide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCT2051200023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200023.